Tissue Valve Firms Target Younger Patients, Want Guidelines To Match
This article was originally published in The Gray Sheet
Executive Summary
Tissue-based heart valve manufacturers are pushing to expand the treatment population for their products to include younger individuals
You may also be interested in...
Research In Brief
Zimmer Trabecular Metal hips: Patients implanted with Zimmer's highly porous Trabecular Metal monoblock hip replacement cups showed up to 41% mean bone density growth around some areas of their hip implants, compared to a 45% loss in density in some areas around titanium cups, over a mean follow-up of 7.7 years in a 17-patient study sponsored by Zimmer. The results are published in the May Journal of Arthroplasty. The study, led by researchers at the Mayo Clinic and the Indiana University Research Foundation, is the first to quantify bone remodeling around hip implants at an "intermediate term" of seven to nine years, according to the company
Research In Brief
Zimmer Trabecular Metal hips: Patients implanted with Zimmer's highly porous Trabecular Metal monoblock hip replacement cups showed up to 41% mean bone density growth around some areas of their hip implants, compared to a 45% loss in density in some areas around titanium cups, over a mean follow-up of 7.7 years in a 17-patient study sponsored by Zimmer. The results are published in the May Journal of Arthroplasty. The study, led by researchers at the Mayo Clinic and the Indiana University Research Foundation, is the first to quantify bone remodeling around hip implants at an "intermediate term" of seven to nine years, according to the company
New Guidelines Support Patient Preference For Tissue Valve Replacements
New guidelines for the treatment of heart valve disease could broaden the use of tissue valve replacement products in younger populations by taking patient preference more seriously